268 related articles for article (PubMed ID: 18655992)
1. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 2: residual conjunctival flora.
Vasavada AR; Gajjar D; Raj SM; Vasavada V; Vasavada V
J Cataract Refract Surg; 2008 Aug; 34(8):1383-8. PubMed ID: 18655992
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin.
Vasavada AR; Gajjar D; Raj SM; Vasavada V; Vasavada V
J Cataract Refract Surg; 2008 Aug; 34(8):1379-82. PubMed ID: 18655991
[TBL] [Abstract][Full Text] [Related]
3. Preoperative topical moxifloxacin 0.5% and povidone-iodine 5.0% versus povidone-iodine 5.0% alone to reduce bacterial colonization in the conjunctival sac.
Halachmi-Eyal O; Lang Y; Keness Y; Miron D
J Cataract Refract Surg; 2009 Dec; 35(12):2109-14. PubMed ID: 19969216
[TBL] [Abstract][Full Text] [Related]
4. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients.
Espiritu CR; Caparas VL; Bolinao JG
J Cataract Refract Surg; 2007 Jan; 33(1):63-8. PubMed ID: 17189795
[TBL] [Abstract][Full Text] [Related]
5. One-day application of topical moxifloxacin 0.5% to select for fluoroquinolone-resistant coagulase-negative Staphylococcus.
He L; Ta CN; Miño de Kaspar H
J Cataract Refract Surg; 2009 Oct; 35(10):1715-8. PubMed ID: 19781465
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora.
Miño de Kaspar H; Kreutzer TC; Aguirre-Romo I; Ta CN; Dudichum J; Bayrhof M; Klauss V; Kampik A
Am J Ophthalmol; 2008 Jan; 145(1):136-142. PubMed ID: 17996212
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery.
Bucci FA; Amico LM; Evans RE
Eye Contact Lens; 2008 Jan; 34(1):39-42. PubMed ID: 18180682
[TBL] [Abstract][Full Text] [Related]
8. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
Am J Ophthalmol; 2005 Sep; 140(3):497-504. PubMed ID: 16083841
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of a combined moxifloxacin/dexamethasone formulation for topical prophylaxis and reduction of inflammation in phacoemulsification: a comparative, double masked clinical trial.
Freitas LL; Soriano E; Muccioli C; Höfling-Lima AL; Belfort R
Curr Med Res Opin; 2007 Dec; 23(12):3123-30. PubMed ID: 17980093
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized comparison of 1-day and 3-day application of topical 0.5% moxifloxacin in eliminating preoperative conjunctival bacteria.
He L; Ta CN; Hu N; Sinnar S; Miño de Kaspar H
J Ocul Pharmacol Ther; 2009 Aug; 25(4):373-8. PubMed ID: 19492956
[TBL] [Abstract][Full Text] [Related]
11. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery.
Arbisser LB
J Cataract Refract Surg; 2008 Jul; 34(7):1114-20. PubMed ID: 18571078
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of efficacy of topical povidone-iodine and different types of fluoroquinolones in the sterilization of bacterial flora on the conjunctiva.
Coskun M; Altintas AG; Anayol MA; Raza S; Celikbilek N; Simsek S
J Ocul Pharmacol Ther; 2011 Dec; 27(6):589-92. PubMed ID: 21834670
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery.
Lane SS; Osher RH; Masket S; Belani S
J Cataract Refract Surg; 2008 Sep; 34(9):1451-9. PubMed ID: 18721703
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial.
Constantinou M; Daniell M; Snibson GR; Vu HT; Taylor HR
Ophthalmology; 2007 Sep; 114(9):1622-9. PubMed ID: 17822972
[TBL] [Abstract][Full Text] [Related]
15. Three-day application of topical ofloxacin reduces the contamination rate of microsurgical knives in cataract surgery: a prospective randomized study.
De Kaspar HM; Chang RT; Shriver EM; Singh K; Egbert PR; Blumenkranz MS; Ta CN
Ophthalmology; 2004 Jul; 111(7):1352-5. PubMed ID: 15234136
[TBL] [Abstract][Full Text] [Related]
16. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.
Torkildsen G; O'Brien TP
Clin Ther; 2008 Nov; 30(11):2005-14. PubMed ID: 19108788
[TBL] [Abstract][Full Text] [Related]
17. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model.
Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
Am J Ophthalmol; 2004 Jul; 138(1):33-7. PubMed ID: 15234279
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Caballero AR; Marquart ME; O'Callaghan RJ; Thibodeaux BA; Johnston KH; Dajcs JJ
Curr Eye Res; 2006 Jan; 31(1):23-9. PubMed ID: 16421016
[TBL] [Abstract][Full Text] [Related]
19. Reduction of conjunctival bacterial flora by povidone-iodine, ofloxacin and chlorhexidine in an outpatient setting.
Barkana Y; Almer Z; Segal O; Lazarovitch Z; Avni I; Zadok D
Acta Ophthalmol Scand; 2005 Jun; 83(3):360-3. PubMed ID: 15948791
[TBL] [Abstract][Full Text] [Related]
20. Comparison of one-day versus one-hour application of topical gatifloxacin in eliminating conjunctival bacterial flora.
Moss JM; Nguyen D; Liu YI; Singh K; Montague A; Egbert PR; Kaspar HM; Ta CN
Ophthalmology; 2008 Nov; 115(11):2013-6. PubMed ID: 18708260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
